Lorlatinib-impurities | Pharmaffiliates

Lorlatinib

Lorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). Reference standards of Lorlatinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Lorlatinib - API Standards 
    [catalogue_number] => PA 12 1490000
    [category_ids] => ,78,75,70,76,82,
    [chemical_name] => 
    [weight] => 406.42
    [form] => C21H19FN6O2
    [cas] => 1454846-35-5
    [pslug] => 1454846-35-5-lorlatinib-api-pa121490000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 12 1490000

Lorlatinib - API Standards


  • Catalogue No.:PA 12 1490000

  • CAS :

    1454846-35-5

  • Molecular Formula : C21H19FN6O2

  • Molecular Weight : 406.42